Loading...

Daniel Pelletier, MD

TitleProfessor of Neurology
InstitutionUniversity of Southern California
DepartmentNeurology
AddressCHP 206 1540 Alcazar St.
Health Sciences Campus
Los Angeles CA 90031
vCardDownload vCard
    Other Positions
    TitleEric and Peggy Lieber Chair in Neurology

    TitleVice Chair, Clinical Research, Department of Neurology

    TitleDivision Chief, Neuro-Immunology and USC Multiple Sclerosis Center


    Collapse Overview 
    Collapse Overview
    Dr. Pelletier is a clinician-scientist born and educated in the Province of Quebec, Canada. After first receiving a bachelor degree in Computer Sciences and studying Artificial Intelligence at the University of Connecticut, Dr. Pelletier received his M.D. degree in 1994 and completed his Neurology training at Laval University and at McGill University. He subsequently received research training in multiple sclerosis and advanced magnetic resonance imaging techniques at the Montreal Neurological Institute.

    He joined the University of California, San Francisco in 1999 as a recipient of a National Multiple Sclerosis Physician Fellowship Award Grant for his work in molecular imaging. He then received the Harry Weaver Neuroscientist Scholar Award in 2005 from the National Multiple Sclerosis Society for his research on magnetic resonance spectroscopy at high field strength and was a recipient of a Distinguished Professorship endowed chair in Neurology at UCSF in 2009. Dr. Pelletier joined Yale University in January 2011 to lead the MS Program as Chief of the Neuro-Immunology Division until March 2015. He recently accepted an appointment at the University of Southern California in Los Angeles to become Vice-Chair of Research and Chief of the Neuro-Immunology and MS Division.

    Dr. Pelletier has received extra-mural research funding from the U.S. National Multiple Sclerosis Society, National Institute of Health, and the Immune Tolerance Network. His work has been published in New England Journal of Medicine, Brain, Annals of Neurology, Lancet Neurology, British Medical Journal, Proceedings of the National Academy of Sciences, Neuroimage, Magnetic Resonance in Medicine, Human Brain Mapping, Neurology, and Human Molecular Genetics.


    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24; 90(17):789-800. PMID: 29686117.
      View in: PubMed
    2. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24; 90(17):777-788. PMID: 29686116.
      View in: PubMed
    3. Thouvenot E, Hinsinger G, Demattei C, Uygunoglu U, Castelnovo G, Pittion-Vouyovitch S, Okuda D, Kantarci O, Pelletier D, Lehmann S, Marin P, Siva A, Lebrun C. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Mult Scler. 2018 Mar 01; 1352458518767043. PMID: 29564952.
      View in: PubMed
    4. Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, Zheng L, Hauser SL, Pelletier D. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018 Feb; 83(2):223-234. PMID: 29328531.
      View in: PubMed
    5. Lebrun C, Kantarci OH, Siva A, Pelletier D, Okuda DT. Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome. Neurol Clin. 2018 Feb; 36(1):59-68. PMID: 29157404.
      View in: PubMed
    6. Azevedo CJ, Jaberzadeh A, Pelletier D. New Concepts Related to Disease Appreciation in Multiple Sclerosis. Neurol Clin. 2018 Feb; 36(1):119-133. PMID: 29157393.
      View in: PubMed
    7. Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, Pelletier D, Azevedo CJ, Lebrun-Frenay C, Siva A, Okuda DT, Kantarci K, Kantarci OH. Cervical spinal cord atrophy: An early marker of progressive MS onset. Neurol Neuroimmunol Neuroinflamm. 2018 Mar; 5(2):e435. PMID: 29435472.
      View in: PubMed
    8. Oh J, Bakshi R, Calabresi PA, Crainiceanu C, Henry RG, Nair G, Papinutto N, Constable RT, Reich DS, Pelletier D, Rooney W, Schwartz D, Tagge I, Shinohara RT, Simon JH, Sicotte NL. The NAIMS cooperative pilot project: Design, implementation and future directions. Mult Scler. 2017 Oct 01; 1352458517739990. PMID: 29106329.
      View in: PubMed
    9. Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D. Radiologically isolated syndrome in children: Clinical and radiologic outcomes. Neurol Neuroimmunol Neuroinflamm. 2017 Nov; 4(6):e395. PMID: 28959703.
      View in: PubMed
    10. Papinutto N, Bakshi R, Bischof A, Calabresi PA, Caverzasi E, Constable RT, Datta E, Kirkish G, Nair G, Oh J, Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Schwartz D, Shinohara RT, Sicotte NL, Stern WA, Tagge I, Tauhid S, Tummala S, Henry RG. Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1 -weighted brain MRI acquisitions. Magn Reson Med. 2018 Mar; 79(3):1595-1601. PMID: 28617996.
      View in: PubMed
    11. Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH, Gupta A, Tsiouris AJ, Kovanlikaya I, Chiang GC, Weinsaft JW, Tanenbaum L, Chen W, Zhu W, Chang S, Lou M, Kopell BH, Kaplitt MG, Devos D, Hirai T, Huang X, Korogi Y, Shtilbans A, Jahng GH, Pelletier D, Gauthier SA, Pitt D, Bush AI, Brittenham GM, Prince MR. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. J Magn Reson Imaging. 2017 Oct; 46(4):951-971. PMID: 28295954.
      View in: PubMed
    12. Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli Ö, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017 Feb 28; 88(9):826-831. PMID: 28148632.
      View in: PubMed
    13. Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016 12; 12(12):714-722. PMID: 27834394.
      View in: PubMed
    14. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510. PMID: 27464262.
      View in: PubMed
    15. Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. J Neurol Sci. 2016 Sep 15; 368:334-6. PMID: 27538659.
      View in: PubMed
    16. Miller AE, Pelletier D. Multiple sclerosis: Rapid diagnosis or right diagnosis? Neurology. 2016 Aug 16; 87(7):652-3. PMID: 27421542.
      View in: PubMed
    17. Prinsen H, de Graaf RA, Mason GF, Pelletier D, Juchem C. Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. J Magn Reson Imaging. 2017 Jan; 45(1):187-198. PMID: 27351712.
      View in: PubMed
    18. Azevedo CJ, Pelletier D. Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? Curr Opin Neurol. 2016 06; 29(3):237-42. PMID: 27070219.
      View in: PubMed
    19. Nourbakhsh B, Azevedo C, Maghzi AH, Spain R, Pelletier D, Waubant E. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis. J Neurol Sci. 2016 Jul 15; 366:229-233. PMID: 27288812.
      View in: PubMed
    20. Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F. Power estimation for non-standardized multisite studies. Neuroimage. 2016 07 01; 134:281-294. PMID: 27039700.
      View in: PubMed
    21. Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Ann Neurol. 2016 Feb; 79(2):288-94. PMID: 26599831.
      View in: PubMed
    22. Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol. 2016 Feb; 23(2):327-32. PMID: 26518224.
      View in: PubMed
    23. Nourbakhsh B, Nunan-Saah J, Maghzi AH, Julian LJ, Spain R, Jin C, Lazar A, Pelletier D, Waubant E. Longitudinal associations between MRI and cognitive changes in very early MS. Mult Scler Relat Disord. 2016 Jan; 5:47-52. PMID: 26856943.
      View in: PubMed
    24. Nourbakhsh B, Azevedo C, Nunan-Saah J, Maghzi AH, Spain R, Pelletier D, Waubant E. Longitudinal associations between brain structural changes and fatigue in early MS. Mult Scler Relat Disord. 2016 Jan; 5:29-33. PMID: 26856940.
      View in: PubMed
    25. Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20. PMID: 27063617.
      View in: PubMed
    26. Maghzi AH, Graves J, Revirajan N, Spain R, Liu S, McCulloch CE, Pelletier D, Green AJ, Waubant E. Retinal axonal loss in very early stages of multiple sclerosis. Eur J Neurol. 2015 Jul; 22(7):1138-41. PMID: 25929276.
      View in: PubMed
    27. Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, Kantarci O, Lebrun Frenay C, Siva A, Okuda DT, Pelletier D. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e102. PMID: 25884012; PMCID: PMC4396526.
    28. Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015 Jun; 42(7):1081-92. PMID: 25833352.
      View in: PubMed
    29. Matsushita T, Madireddy L, Sprenger T, Khankhanian P, Magon S, Naegelin Y, Caverzasi E, Lindberg RL, Kappos L, Hauser SL, Oksenberg JR, Henry R, Pelletier D, Baranzini SE. Genetic associations with brain cortical thickness in multiple sclerosis. Genes Brain Behav. 2015 Feb; 14(2):217-27. PMID: 25684059; PMCID: PMC4857705.
    30. Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82. PMID: 25892977; PMCID: PMC4399770.
    31. Bhargava P, Cassard S, Steele SU, Azevedo C, Pelletier D, Sugar EA, Waubant E, Mowry EM. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014 Nov; 39(2):288-93. PMID: 25311447.
      View in: PubMed
    32. Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, Jin C, Green AJ, McCulloch CE, Pelletier D, Waubant E. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014 Nov; 3(6):720-7. PMID: 25891551.
      View in: PubMed
    33. Azevedo CJ, Kornak J, Chu P, Sampat M, Okuda DT, Cree BA, Nelson SJ, Hauser SL, Pelletier D. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol. 2014 Aug; 76(2):269-78. PMID: 25043416; PMCID: PMC4142752.
    34. Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, Pelletier D, Pouwels PJ, Smith SA, Wheeler-Kingshott CA, Stankoff B, Yousry T, Miller DH. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014 Aug; 13(8):807-22. PMID: 25008549.
      View in: PubMed
    35. Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol. 2014 Jul 01; 71(7):840-7. PMID: 24839987.
      View in: PubMed
    36. Waubant E, Maghzi AH, Revirajan N, Spain R, Julian L, Mowry EM, Marcus J, Liu S, Jin C, Green A, McCulloch CE, Pelletier D. A randomized controlled phase II trial of riluzole in early multiple sclerosis. Ann Clin Transl Neurol. 2014 May; 1(5):340-7. PMID: 25356404; PMCID: PMC4184685.
    37. Shi Y, Lai R, Wang DJ, Pelletier D, Mohr D, Sicotte N, Toga AW. Metric optimization for surface analysis in the Laplace-Beltrami embedding space. IEEE Trans Med Imaging. 2014 Jul; 33(7):1447-63. PMID: 24686245; PMCID: PMC4079755.
    38. Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014; 9(3):e90509. PMID: 24598783; PMCID: PMC3943959.
    39. Chitnis T, Guttmann CR, Zaitsev A, Musallam A, Weinstock-Guttman B, Yeh A, Rodriguez M, Ness J, Gorman MP, Healy BC, Kuntz N, Chabas D, Strober JB, Waubant E, Krupp L, Pelletier D, Erickson B, Bergsland N, Zivadinov R. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013 Nov 13; 13:173. PMID: 24225378; PMCID: PMC3832402.
    40. Hannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, Pittman B, Lee JY, O'Connor KC, Pelletier D, Carson RE. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun. 2013 Oct; 33:131-8. PMID: 23850810.
      View in: PubMed
    41. Nickles D, Chen HP, Li MM, Khankhanian P, Madireddy L, Caillier SJ, Santaniello A, Cree BA, Pelletier D, Hauser SL, Oksenberg JR, Baranzini SE. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet. 2013 Oct 15; 22(20):4194-205. PMID: 23748426; PMCID: PMC3781642.
    42. Burns MN, Nawacki E, Kwasny MJ, Pelletier D, Mohr DC. Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med. 2014 Jan; 44(2):349-59. PMID: 23680407; PMCID: PMC4123859.
    43. Gourraud PA, Sdika M, Khankhanian P, Henry RG, Beheshtian A, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D, Baranzini SE. A genome-wide association study of brain lesion distribution in multiple sclerosis. Brain. 2013 Apr; 136(Pt 4):1012-24. PMID: 23412934; PMCID: PMC3613709.
    44. Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology. 2013 Jan 08; 80(2):210-9. PMID: 23296131; PMCID: PMC3589190.
    45. Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013 Jan; 75(1):76-82. PMID: 23197840; PMCID: PMC3538885.
    46. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87. PMID: 23280794.
      View in: PubMed
    47. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012 Aug; 72(2):234-40. PMID: 22926855; PMCID: PMC3430977.
    48. Gold SM, O'Connor MF, Gill R, Kern KC, Shi Y, Henry RG, Pelletier D, Mohr DC, Sicotte NL. Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp. 2014 Jan; 35(1):30-7. PMID: 22847919; PMCID: PMC3748203.
    49. Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul 31; 79(5):412-9. PMID: 22786596; PMCID: PMC3405245.
    50. Bian W, Harter K, Hammond-Rosenbluth KE, Lupo JM, Xu D, Kelley DA, Vigneron DB, Nelson SJ, Pelletier D. A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler. 2013 Jan; 19(1):69-75. PMID: 22641301.
      View in: PubMed
    51. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology. 2012 Apr 10; 78(15):1171-8. PMID: 22459680; PMCID: PMC3320055.
    52. Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, DeLuca G, De Stefano N, Erickson BJ, Evangelou N, Fazekas F, Geurts JJ, Lucchinetti C, Miller DH, Pelletier D, Popescu BF, Lassmann H. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 Apr; 11(4):349-60. PMID: 22441196.
      View in: PubMed
    53. Riley C, Azevedo C, Bailey M, Pelletier D. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert Rev Neurother. 2012 Mar; 12(3):323-33. PMID: 22364331.
      View in: PubMed
    54. Lebrun C, Le Page E, Kantarci O, Siva A, Pelletier D, Okuda DT. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012 Sep; 18(9):1297-302. PMID: 22300971.
      View in: PubMed
    55. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012 Jan 26; 366(4):339-47. PMID: 22276823.
      View in: PubMed
    56. Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011 Dec; 68(12):1514-20. PMID: 22159052.
      View in: PubMed
    57. Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011 Sep; 17(9):1098-106. PMID: 21586487.
      View in: PubMed
    58. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 Feb 03; 6(2):e16664. PMID: 21304907; PMCID: PMC3033401.
    59. Filippi M, Rocca MA, Barkhof F, Bakshi R, Fazekas F, Khan O, Pelletier D, Rovira A, Simon J. Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective. AJNR Am J Neuroradiol. 2011 Mar; 32(3):424-7. PMID: 21292801.
      View in: PubMed
    60. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92. PMID: 21270417; PMCID: PMC3053327.
    61. Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med. 2011 Jan 18; 3(1):3. PMID: 21244703; PMCID: PMC3092088.
    62. Shi Y, Lai R, Gill R, Pelletier D, Mohr D, Sicotte N, Toga AW. Conformal metric optimization on surface (CMOS) for deformation and mapping in Laplace-Beltrami embedding space. Med Image Comput Comput Assist Interv. 2011; 14(Pt 2):327-34. PMID: 21995045.
      View in: PubMed
    63. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain. 2010 Sep; 133(9):2603-11. PMID: 20802204; PMCID: PMC2929334.
    64. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging. 2010 Feb; 28(2):163-70. PMID: 19695821.
      View in: PubMed
    65. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, Strober JB, Soares B, Wintermark M, Pelletier D. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009 Aug; 66(8):967-71. PMID: 19667217.
      View in: PubMed
    66. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5. PMID: 19451531; PMCID: PMC2683738.
    67. Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci. 2009 Jul 15; 282(1-2):61-6. PMID: 19394969.
      View in: PubMed
    68. Sdika M, Pelletier D. Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping. Hum Brain Mapp. 2009 Apr; 30(4):1060-7. PMID: 18412131.
      View in: PubMed
    69. Chabas D, Pelletier D. Sorting through the pediatric MS spectrum with brain MRI. Nat Rev Neurol. 2009 Apr; 5(4):186-8. PMID: 19347023.
      View in: PubMed
    70. Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM, Kappos L. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009 Jun 01; 18(11):2078-90. PMID: 19286671; PMCID: PMC2678928.
    71. Metcalf M, Xu D, Okuda DT, Carvajal L, Srinivasan R, Kelley DA, Mukherjee P, Nelson SJ, Vigneron DB, Pelletier D. High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients. J Neuroimaging. 2010 Apr; 20(2):141-7. PMID: 19187478; PMCID: PMC2874605.
    72. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009 Mar 03; 72(9):800-5. PMID: 19073949.
      View in: PubMed
    73. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, Nelson SJ, Pelletier D. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol. 2008 Dec; 64(6):707-13. PMID: 19107998.
      View in: PubMed
    74. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9. PMID: 19022862; PMCID: PMC2638695.
    75. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78. PMID: 19010793; PMCID: PMC4334814.
    76. Corvol JC, Pelletier D, Henry RG, Caillier SJ, Wang J, Pappas D, Casazza S, Okuda DT, Hauser SL, Oksenberg JR, Baranzini SE. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A. 2008 Aug 19; 105(33):11839-44. PMID: 18689680; PMCID: PMC2504481.
    77. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA, Filippi M. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008 Jul; 7(7):615-25. PMID: 18565455; PMCID: PMC2586926.
    78. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008 Nov; 79(11):1236-44. PMID: 18469033; PMCID: PMC4827711.
    79. Hammond KE, Lupo JM, Xu D, Metcalf M, Kelley DA, Pelletier D, Chang SM, Mukherjee P, Vigneron DB, Nelson SJ. Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage. 2008 Feb 15; 39(4):1682-92. PMID: 18096412; PMCID: PMC2377156.
    80. Chung S, Pelletier D, Sdika M, Lu Y, Berman JI, Henry RG. Whole brain voxel-wise analysis of single-subject serial DTI by permutation testing. Neuroimage. 2008 Feb 15; 39(4):1693-705. PMID: 18082426; PMCID: PMC2276665.
    81. Ratiney H, Noworolski SM, Sdika M, Srinivasan R, Henry RG, Nelson SJ, Pelletier D. Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data. MAGMA. 2007 Jun; 20(3):143-55. PMID: 17602253; PMCID: PMC2798973.
    82. Oh J, Han ET, Lee MC, Nelson SJ, Pelletier D. Multislice brain myelin water fractions at 3T in multiple sclerosis. J Neuroimaging. 2007 Apr; 17(2):156-63. PMID: 17441837.
      View in: PubMed
    83. Srinivasan R, Cunningham C, Chen A, Vigneron D, Hurd R, Nelson S, Pelletier D. TE-averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T. Neuroimage. 2006 May 01; 30(4):1171-8. PMID: 16431138.
      View in: PubMed
    84. Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006 Jan; 20(1):27-36. PMID: 15894458.
      View in: PubMed
    85. Oh J, Han ET, Pelletier D, Nelson SJ. Measurement of in vivo multi-component T2 relaxation times for brain tissue using multi-slice T2 prep at 1.5 and 3 T. Magn Reson Imaging. 2006 Jan; 24(1):33-43. PMID: 16410176.
      View in: PubMed
    86. Panossian LA, Garga NI, Pelletier D. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol. 2005 Nov; 58(5):812-3. PMID: 16240360.
      View in: PubMed
    87. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 Jul 28; 353(4):375-81. PMID: 15947078.
      View in: PubMed
    88. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005 May; 128(Pt 5):1016-25. PMID: 15758036.
      View in: PubMed
    89. Cox D, Pelletier D, Genain C, Majumdar S, Lu Y, Nelson S, Mohr DC. The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler. 2004 Dec; 10(6):626-9. PMID: 15584486.
      View in: PubMed
    90. Oh J, Henry RG, Genain C, Nelson SJ, Pelletier D. Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging. J Neurol Neurosurg Psychiatry. 2004 Sep; 75(9):1281-6. PMID: 15314115; PMCID: PMC1739254.
    91. Oh J, Pelletier D, Nelson SJ. Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch Neurol. 2004 Jul; 61(7):1081-6. PMID: 15262739.
      View in: PubMed
    92. Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging. 2004 Jul; 14(3 Suppl):11S-19S. PMID: 15228755.
      View in: PubMed
    93. Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil SS. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler. 2004 Jun; 10 Suppl 1:S58-61. PMID: 15218811.
      View in: PubMed
    94. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004 Mar 27; 328(7442):731. PMID: 15033880; PMCID: PMC381319.
    95. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med. 2004 Mar; 51(3):435-40. PMID: 15004781.
      View in: PubMed
    96. Henry RG, Oh J, Nelson SJ, Pelletier D. Directional diffusion in relapsing-remitting multiple sclerosis: a possible in vivo signature of Wallerian degeneration. J Magn Reson Imaging. 2003 Oct; 18(4):420-6. PMID: 14508778.
      View in: PubMed
    97. Pelletier D, Nelson SJ, Oh J, Antel JP, Kita M, Zamvil SS, Goodkin DE. MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry. 2003 Jul; 74(7):950-2. PMID: 12810788; PMCID: PMC1738553.
    98. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003 Mar; 72(3):710-6. PMID: 12557126; PMCID: PMC1180245.
    99. Srinivasan R, Henry R, Pelletier D, Nelson S. Standardized, reproducible, high resolution global measurements of T1 relaxation metrics in cases of multiple sclerosis. AJNR Am J Neuroradiol. 2003 Jan; 24(1):58-67. PMID: 12533328.
      View in: PubMed
    100. Grenier D, Pelletier D, Normandeau M, Newitt D, Nelson S, Goodkin DE, Majumdar S. T2 relaxation time histograms in multiple sclerosis. Magn Reson Imaging. 2002 Dec; 20(10):733-41. PMID: 12591569.
      View in: PubMed
    101. Blum D, Yonelinas AP, Luks T, Newitt D, Oh J, Lu Y, Nelson S, Goodkin D, Pelletier D. Dissociating perceptual and conceptual implicit memory in multiple sclerosis patients. Brain Cogn. 2002 Oct; 50(1):51-61. PMID: 12372351.
      View in: PubMed
    102. Pelletier D, Nelson SJ, Grenier D, Lu Y, Genain C, Goodkin DE. 3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain. Magn Reson Imaging. 2002 Oct; 20(8):599-606. PMID: 12467867.
      View in: PubMed
    103. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2001 Nov; 248(11):979-86. PMID: 11757963.
      View in: PubMed
    104. Pike GB, De Stefano N, Narayanan S, Worsley KJ, Pelletier D, Francis GS, Antel JP, Arnold DL. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000 Jun; 215(3):824-30. PMID: 10831705.
      View in: PubMed
    105. Prat A, Pelletier D, Duquette P, Arnold DL, Antel JP. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol. 2000 Feb; 47(2):234-7. PMID: 10665495.
      View in: PubMed
    106. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol. 1999 Feb; 45(2):247-50. PMID: 9989628.
      View in: PubMed